Robert Herscowitz, MD
Pulmonary Disease · Alexandria, VANPI 1801838776
Payments from drug & device makers
Across 59 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$223
- GSK$210
- AstraZeneca$189
- Sanofi$144
- Genentech USA, Inc.$93
- Philips North America LLC$44
- plus $137 from 6 others
What the payments were for
- Food & beverage$1,01297%
- Education$283%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 10 | $223 |
| GSK | 15 | $210 |
| AstraZeneca | 11 | $189 |
| Sanofi | 9 | $144 |
| Genentech USA, Inc. | 4 | $93 |
| Philips North America LLC | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $33 |
| Mylan Specialty L.p. | 2 | $32 |
| Insmed, Inc. | 1 | $22 |
| Grifols USA, LLC | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Circassia Inc. | 1 | $12 |
How this compares
$1,040 in reported general payments places this provider in the 35th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 368 | $328,238 |
| OfevNintedanib Esylate | 12 | $156,426 |
| Breo ElliptaFluticasone/Vilanterol | 220 | $142,062 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 70 | $86,395 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 114 | $80,536 |
| Spiriva RespimatTiotropium Bromide | 62 | $62,551 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 62 | $57,611 |
| Dupixent SyringeDupilumab | 13 | $48,356 |
| Spiriva HandihalerTiotropium Bromide | 17 | $18,954 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $17,135 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $16,694 |
| SymbicortBudesonide/Formoterol Fumarate | 36 | $11,105 |
| Arnuity ElliptaFluticasone Furoate | 36 | $10,903 |
| Tiotropium Bromide | 14 | $9,036 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 42 | $8,673 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $210 | $578,873766 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $223 | $276,588136 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $189 | $102,150121 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $17 | $5,70219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Alexandria
- Katherine Cox-FlahertyAlexandria$30K
- Steven NathanFalls Church$2.5M
- Shilpa JohriRichmond$1.7M
- Omar MinaiHopewell$1.3M
- Vijay SubramaniamWilliamsburg$1.3M
- Rabih HalabiFalls Church$604K
- Patricia SimeRichmond$572K
- Apostolos PerelasRichmond$567K
- Hannah MannemCharlottesville$326K
- Ray ShepherdRichmond$303K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.